the Safety / Feasibility /MORENO Score/Regulation / Secondary Transfers / SAMU 29 / Current PracticesESMORTSAB19NCT06555874
Evaluation of the MORENO Score for the Regulation
An observational study of the Safety / Feasibility /MORENO Score/Regulation / Secondary Transfers / SAMU 29 / Current Practices, run by University Hospital, Brest at 1 site in France.
Trial summary
The main objective of this work is therefore to evaluate the safety and feasibility of the MORENO score for the regulation of secondary transfers to the SAMU 29 compared to current practices. Read more about this study
- Who is it for?
- Ages 18 to 120 years
- Conditions the study is for
- the Safety / Feasibility /MORENO Score/Regulation / Secondary Transfers / SAMU 29 / Current Practices
- How many people
- 1,500 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jun 2020to 30 Jun 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- All sexes
- Adult, Older adult
Study population: All adult patients having benefited from a transfer
Who may be able to join
- All adult patients having benefited from a transfer regulated by the SAMU 29 of adult patients on the Finistère territory over a predefined period of time
Who cannot join
- Pediatric patient transfers
- Maritime transfers
- Transfers for which the collected information does not allow to establish the MORENO score.
- Patients under judicial protection (guardianship, curatorship,..)
- Opposition
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the MORENO Score for the Regulation of Secondary Transfers to the UAS-SMUR in Brest in Finistère in 2020
The main objective of this work is therefore to evaluate the safety and feasibility of the MORENO score for the regulation of secondary transfers to the SAMU 29 compared to current practices.
Read the detailed description
Today, there is an increase in the number of secondary transfers and paramedical transport between the different hospitals in a territory. They have been promoted by the SFMU (French Society of Emergency Medicine) since 2012.
The sharp increase in the number of calls for SAMU regulation means that decisions must be made quickly and safely regarding transport requiring or not requiring a medical presence. The development of a decision support tool for the level of medicalisation of a transfer therefore seems necessary. However, there is currently no recommendation in France.
The MORENO score has already been used in a hospital in the Var, as well as in Spain and Greece. Prior validation of this score in our health territory is essential before setting up an operational procedure. Using a list of simple clinical items, this score enables us to assess whether or not it is necessary to medicalise a transfer.
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluation of the concordance of the MORENO score for the regulation of secondary transfers at SAMU 29 and our current practices
Rate of agreement between our practices and the MORENO score strategy.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Aug 2024
- Study start1 Jun 2020
- Primary completion30 Jun 2021
- Study completion30 Jun 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for the Safety / Feasibility /MORENO Score/Regulation / Secondary Transfers / SAMU 29 / Current PracticesStudies of the same condition, open and under way.
- More trials run by University Hospital, BrestThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Retrospective
- Enrolment
- 1,500 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Brest
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06555874
- Sponsor's protocol ID
- 29BRC20.0075
- Acronym
- ESMORTSAB19
- Status last verified
- Aug 2024
- First submitted
- 13 Aug 2024
- Last updated
- 15 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All collected data that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 15 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the MORENO Score for the Regulation of Secondary Transfers to the UAS-SMUR in Brest in Finistère in 2020
- ClinicalTrials.gov ID
- NCT06555874
- Acronym / sponsor ID
- ESMORTSAB19 / 29BRC20.0075
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,500 participants (actual)
- Lead sponsor
- University Hospital, BrestUniversity, hospital or other
- Study start
- 1 Jun 2020 (actual)
- Primary completion
- 30 Jun 2021 (actual)
- Study completion
- 30 Jun 2021 (actual)
- First posted
- 15 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this work is therefore to evaluate the safety and feasibility of the MORENO score for the regulation of secondary transfers to the SAMU 29 compared to current practices.
Detailed description
Today, there is an increase in the number of secondary transfers and paramedical transport between the different hospitals in a territory. They have been promoted by the SFMU (French Society of Emergency Medicine) since 2012.
The sharp increase in the number of calls for SAMU regulation means that decisions must be made quickly and safely regarding transport requiring or not requiring a medical presence. The development of a decision support tool for the level of medicalisation of a transfer therefore seems necessary. However, there is currently no recommendation in France.
The MORENO score has already been used in a hospital in the Var, as well as in Spain and Greece. Prior validation of this score in our health territory is essential before setting up an operational procedure. Using a list of simple clinical items, this score enables us to assess whether or not it is necessary to medicalise a transfer.
Study design
- Observational model
- Other
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 to 120 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All adult patients having benefited from a transfer
Key inclusion criteria (1 listed)
- All adult patients having benefited from a transfer regulated by the SAMU 29 of adult patients on the Finistère territory over a predefined period of time
Key exclusion criteria (5 listed)
- Pediatric patient transfers
- Maritime transfers
- Transfers for which the collected information does not allow to establish the MORENO score.
- Patients under judicial protection (guardianship, curatorship,..)
- Opposition
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Evaluation of the concordance of the MORENO score for the regulation of secondary transfers at SAMU 29 and our current practices
Time frame: 1 year
Rate of agreement between our practices and the MORENO score strategy.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Aug 2024.
- Individual participant dataSharing planned: Yes. All collected data that underlie results in a publication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of the Safety / Feasibility /MORENO Score/Regulation / Secondary Transfers / SAMU 29 / Current Practices, run by University Hospital, Brest at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluation of the concordance of the MORENO score for the regulation of secondary transfers at SAMU 29 and our current practices (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Aug 2024.